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1. Introduction 
Acute myocardial infarction (AMI) is a leading cause of death worldwide. (Wollert and 
Drexler, 2010) Despite improvements in survival rate after AMI with recent medical 
advances (Jackson, et al., 2001), the reduced heart function attributed to irreversible loss of 
viable cardiomyocytes remains a major clinical problem (Timmermans, et al., 2003). Typical 
MI results in large-scale loss of cardiac muscle, often a billion or more myocytes. (Laflamme 
and Murry, 2005) The loss of myocardial cell mass and the inability of remaining cells to 
adequately compensate through hypertrophic or hyperplastic responses result in the 
development of heart failure due to ventricular dysfunction (Jain, et al., 2005).  Endogenous 
repair mechanisms of the adult human heart are not sufficient for meaningful tissue 
regeneration, so muscle lost is replaced by non-contractile fibrotic scar tissue, initiating 
progressive heart failure (Laflamme, et al., 2007). Heart failure is the number one cause of 
hospitalization in US citizens over 65 of age and has a significant economic impact 
(Laflamme and Murry, 2005). Despite recent advances in treatment options, mortality 
remains unacceptably high (Ertl, et al., 1993, Pfeffer and Braunwald, 1990, Towbin and 
Bowles, 2002) with >50% of all patients succumbing within 5 years of the initial diagnosis of 
heart failure (Jain, et al., 2005). Improved medical and surgical treatments for patients after 
AMI have led to the decrease in early mortality, but as a result there of a higher incidence of 
heart feailure. (Wollert and Drexler, 2010) In some patients with advanced disease, cardiac 
transplantation may be an option, but due to organ shortage, its practical use is limited to 
end-stage heart failure.  
In the current clinical setting, early reperfusion by percutaneous coronary intervention (PCI) 
including intra-coronary stenting is the treatment of choice in the situation of acute MI 
(Topol, 2003). In patients with diffused coronary artery disease associated with severe 
ischemic cardiomyopathy, coronary artery bypass grafting (CABG) remains the optimal way 
of coronary revascularization, and is associated with improved survival and reduction of 
angina (Detre, et al., 1996, Pell, et al., 2004). Although surgical and catheter-based 
revascularization of ischemic myocardium can treat angina, reduce the risk of MI, and 
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improve cardiac function, the viability of severely ischemic myocardium, necrotic 
myocardium, or both cannot be restored. (Patel, et al., 2005) Current pharmacologic and 
interventional strategies are unsuccessful to regenerate dead myocardium and failed to 
address the clinical challenge caused by the early loss of cardiomyocytes (Charwat, et al., 
2008). Moreover, none of our current therapies addresses the underlying cause of the 
remodeling process, namely the damage to the cardiomyocytes and the vasculature in the 
ischemic tissue (Wollert, 2008). Therefore, new cardiovascular therapies must be elaborated 
to promote myocardial repair and regeneration, this “Holy Grail” represents a major 
challenge in the treatment of ischemic cardiovascular diseases. 
2. Stem cells for myocardial repair 
One approach to counteract the effects of myocardial dysfunction could be replacement of 
damaged contractile cells by healthy myocytes or progenitor cells with the potential of 
becoming new functional cardiomyocytes (Evans, et al., 2007).  There is growing evidence 
suggesting that heart muscle has the ability to regenerate through activation of cardiac 
resident stem cells (CSC), or through recruitment of progenitor stem cells population from 
other tissues, such as the bone marrow (BM) (Charwat, et al., 2008).  Cellular transplantation 
is a potential approach to improve healing of the ischemic heart, to repopulate the injured 
myocardium (Dowell, et al., 2003), to treat heart failure (Dowell, et al., 2003, Raeburn, et al., 
2002) and restore cardiac function (Hassink, et al., 2003, Orlic, et al., 2002). Experimental 
studies have shown that adult bone marrow stem cells (BMSC) are capable of differentiation 
(Blau, et al., 2001, Goodell, et al., 2001, Jackson, et al., 2002, Krause, et al., 2001), regeneration 
of infarcted myocardium, induction of myogenesis, as well as promotion of angiogenesis, 
ultimately leading to a better cardiac contractile performance (Dowell, et al., 2003, Kocher, et 
al., 2001, Orlic, et al., 2001, 2003, Orlic, et al., 2001, Orlic, et al., 2001, Shake, et al., 2002, 
Strauer, et al., 2002, Tomita, et al., 1999, Tomita, et al., 2002). A variety of embryonic and 
adult-derived cell types have been investigated for their capacity to mediate cardiac and 
vascular repair (Psaltis, et al., 2008). Nowadays, several cell candidates have been recently 
investigated for the treatment of ischemic cardiomyopathy such as fetal (Li, et al., 1997) and 
neonatal (Watanabe, et al., 1998) cardiomyocytes, embryonic stem cells (Min, et al., 2002, 
Min, et al., 2003), cardiac resident stem cells, skeletal myoblasts (Leor, et al., 1996, Menasche, 
et al., 2001, Menasche, et al., 2003, Murry, et al., 1996, Taylor, et al., 1998) and endothelial 
progenitor cells (Kawamoto and Losordo, 2008, Kawamoto, et al., 2003, Kocher, et al., 2001). 
The bone marrow is known to be an excellent reservoir for many adult stem cells and BMSC 
have been used to treat hematologic disorders for decades (Liao, et al., 2007).  Bone marrow, 
which is easily accessible, is presently the most frequent source of cells used for clinical 
cardiac repair (Dimmeler, et al., 2005, Kocher, et al., 2007). Bone marrow-derived cells 
contain a complex assortment of progenitor cells, including hematopoietic stem cells (HSC), 
side population (SP) cells, mesenchymal or stromal, stem cells (MSC), and multipotent adult 
progenitor cells (MAPC), a subset of MSC (Barbash, et al., 2003, Jackson, et al., 2001, Perin, et 
al., 2003, Strauer, et al., 2002, Toma, et al., 2002).  Other progenitor/stem cell populations 
investigated include (Kocher, et al., 2007): fat tissue-derived multipotent stem cells (Planat-
Benard, et al., 2004), multipotential cells from bone marrow (Jiang, et al., 2002),  skeletal 
muscle, somatic stem cells from placental cord blood (Kogler, et al., 2004), amniotic fluid-
derived stem cells (De Coppi, et al., 2007), circulating endothelial progenitor cells (EPC), and 
cardiac resident progenitor cells (CPC) are already predisposed to adopt a cardiomyocyte 
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phenotype (Beltrami, et al., 2003, Oh, et al., 2003). Positive results from animal studies have 
prompted several clinical trials to ascertain the safety, feasibility and efficacy of cell therapy.  
Despite the fact that the exact mechanisms underpinning stem cell therapy have not been 
yet elucidated and are still intensely debated, cell therapy has already been introduced into 
the clinical setting (Dowell, et al., 2003, Weisel, et al., 2004, Wollert and Drexler, 2005). 
Cell transplantation treatments are faced with many technical and practical issues, and are 
limited to autologous cells, which require bone marrow aspirations, muscle biopsies or 
blood sampling with cells sorting and/or culture. Moreover, they are unable to deliver large 
cell numbers that would survive the peri-transplantation period (Reinecke, et al., 1999, 
Shake, et al., 2002, Wollert and Drexler, 2005, Zhang, et al., 2001).  Over the past several 
years, a surge of experimental data from pre-clinical and clinical studies has emerged 
providing both a proof of concept and therapeutic promises for post-MI cardiac repair and 
regeneration using these cell therapies (Jain, et al., 2005). Despite all the excitement in stem 
cell research resulting from initial experimental data and preliminary clinical trials, many 
crucial questions regarding stem cells therapy still remain to be answered. The most 
important ones being what are the exact mechanisms underlying their beneficial effects, and 
which cell type is the most appropriate for clinical application? A major obstacle to the 
identification of the optimal cell therapy is that the fate of the implanted cells and the nature 
of their beneficial effects are ill defined (Evans, et al., 2007).  Moreover, a clear 
characterization of the cellular effects of stem cell transplantation is critical to avoid 
potentially adverse consequences and to improve the outcome (Evans, et al., 2007). A better 
understanding is fundamental for the development of new therapeutics, and to optimize 
stem cell applications in the treatment of ischemic cardiovascular diseases. 
3. Various cell candidates for cardiac repair 
A myriad of cell types have been tested experimentally, each of them being usually credited 
by its advocates of a high "regeneration" potential. This has led to a flurry of clinical trials 
entailing the use of skeletal myoblasts or bone marrow-derived cells either unfractionated or 
enriched in progenitor subpopulations. (Menasche, 2009) There is currently uncertainty as to 
which of the stem cell population is most potent in stimulating angiogenesis and cardiac 
repair. Theoretically, many stem and progenitor cell populations are potential candidates to 
be used for cardiac repair and to treat ischemic cardiomyopathy. Each cell type possesses its 
own profile of advantages, limitations and practicability issues (Wollert, 2008). It, appears 
that not "one cell fits all" but that the selection of the cell type should be tailored to the 
primary clinical indication. (Menasche, 2009) Studies comparing the regenerative capacity of 
distinct cell populations are scarce. (Wollert, 2008) As replacement therapy in humans, the 
estimates are that 108-109 cells might be needed to replace those lost after a moderate size 
AMI. Accordingly, an important issue in cell therapy is scalability and the ability to deliver a 
large amount of cells into the ischemic myocardium. It does not make sense to develop an 
"ideal" cell in a culture dish, if we remain unable to deliver it appropriately and to keep it 
alive, at least for a while, which requires to improve on the delivery techniques and to 
provide cells along with the vascular and extracellular matrix type of support necessary for 
their survival and patterning. (Menasche, 2009) Another issue which must be considered is 
autologous versus non-autologous source of donor cells. (Evans, et al., 2007) Autologous 
have the advantage of avoiding inflammatory response and immune rejection. However, to 
be useful for broad clinical application, cells must be readily available in sufficient number 
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or easily to harvest and isolate. Herein are some characteristics of the most commonly used 
adult stem cells for cardiac repair. 
3.1 Primary remuscularization by myogenic cells 
When contemplating how cell therapy might benefit the recently infarcted heart, perhaps 
the most obvious strategy is remuscularization, that is, the replacement of the necrotic 
myocardium with viable new muscle cells. (Laflamme, et al., 2007) Strong proof-of-principle 
data to support this approach were provided by studies in which committed 
cardiomyocytes from fetal (Li, et al., 1997) and neonatal (Watanabe, et al., 1998) sources 
were transplanted into murine or rat model of ischemic myocardium. The implanted 
myocytes formed stable intracardiac grafts and resulted in improvement in cardiac function. 
(Leor, et al., 1996, Li, et al., 1996) As expected for terminally differentiated cardiomyocytes, 
the implanted cells retained their contractile phenotype and expressed the necessary 
elements for intercellular electrical communication such as gap junction proteins. 
(Laflamme, et al., 2007) Another myogenic cell type, skeletal muscle satellite cells commonly 
referred to as skeletal myoblast has been extensively studied in animals and clinical trials. 
(Menasche, 2008, Menasche, et al., 2001, Menasche, et al., 2003, Murry, et al., 1996, Taylor, et 
al., 1998) Skeletal myoblasts have undergone extensive preclinical testing that has 
consistently demonstrated their ability to preserve postinfarct left ventricular function and 
to limit remodelling. (Menasche, 2008) Indeed, skeletal myoblasts, the progenitor cell that 
mediate normal regeneration of skeletal striated muscle, have a number of attractive 
properties for cardiac cell therapies, including relative resistance to ischemia, potentially 
autologous donor source from readily accessible muscle biopsies, paracrine effects by 
secretions of growth factors, and the capacity for tremendous in vitro expansion. (Dowell, et 
al., 2003, Laflamme, et al., 2007, Menasche, 2008, 2009) The primary disadvantage of skeletal 
myoblasts is simply that they differentiate into the wrong form of striated muscle, i.e. 
skeletal rather than cardiac, with the caveat of severe ventricular arrhythmias requiring the 
implantation of automatic implantable cardioverter-defibrillator (AICD) devices. 
(Laflamme, et al., 2007, Menasche, 2011, Menasche, et al., 2003)  
3.2 Hematopoietic stem cells (HSC) 
Commonly referred as bone marrow stem cells (BMSC), HSC constitute a small cell 
population of the bone marrow, perhaps as few as 1:10,000 bone marrow mononuclear cells. 
(Anversa, et al., 2004, Harrison, et al., 1988) HSC can be enriched using various technologies 
to high purity on the basis of surface markers (lineage-, c-kit+, Sca-1+, CD38high, CD34, or the 
more immature marker protein CD133) (Dimmeler and Zeiher, 2004, Orlic, et al., 2002). 
These cells represent the prototypic adult stem cell population. The ability of HSC to 
reconstitute the hematopoietic system of a myeloablated host led to the first clinical 
application of adult stem cells more than three decades ago. (Liao, et al., 2007) HSC can self-
renew and were shown to trans-differentiate into multiple lineages, including endothelial 
cells (Nygren, et al., 2004, Orlic, et al., 2002, Urbich and Dimmeler, 2004), and can contribute 
to the regeneration of a variety of non-hematopoietic lineages in multiple organs, including 
myocardium (Jackson, et al., 2001, Orlic, 2003, 2004). The interest in stem cells for cardiac 
regeneration started in 2001 with the observation of Orlic et al who injected Lin- ckit+ bone 
marrow-derived HSC that were able to repair acute MI in mice by transdifferentiating into 
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cardiomyocytes and vascular cells (Orlic, et al., 2001).  To date, the HSC appear to be the 
most versatile stem cells across all lineages, since adult somatic HSC may share a similar 
developmental plasticity commonly seen in embryonic stem cells (Anversa, et al., 2004). The 
use of hematopoietic progenitors stem cells appears to uniformly induce neovascularization 
that seems to be a prerequisite of the successful functional repair. HSC can be used to repair 
infarcted hearts by regenerating new cardiomyocytes and vascular endothelium in response 
to ischemic injury (Jackson, et al., 2001, Kocher, et al., 2001, Nygren, et al., 2004, Orlic, et al., 
2001).  
3.3 Circulating stem cells 
Endothelial progenitor cells (EPCs) are a heterogeneous group of endothelial cell (EC) 
precursors originating from the hematopoietic compartment of the bone marrow. (Asahara, 
et al., 1999) EPCs share many surface markers (hematopoietic markers CD133, CD34, 
vascular endothelial growth factor receptor-2 (Flk-1)) and biological properties with 
hematopoietic stem cell (HSC). (Asahara, et al., 1999, Gehling, et al., 2000, Shi, et al., 1998) 
EPCs are isolated from the bone marrow or from the peripheral circulation and expanded in 
vitro. (Liao, et al., 2007) After a few days in culture in endothelial cell medium 
supplemented with growth factors, EPC phenotype can be confirmed by direct fluorescent 
staining with 1,1’-dioctadecyl-3-3-3,3’-tetramethylindocarbocyanine (Dil)-labeled acetylated 
low-density lipoprotein (DiLDL) and fluorescein isocyanate (FITC)-labeled Ulex europaeus 
agglutinin-I (lectin). Dual stained cells positive for both DiLDL and lectin are considered 
EPC, see Fig. 1. EPCs are subdivided into “early”, and “late” also referred as outgrowth of 
EC (OECs). (Hur, et al., 2004, Smadja, et al., 2007, Yoon, et al., 2005) EPCs have the homing 
capacity to sites of active angiogenesis, where they participate in the repair of various 
tissues, including the heart. (Asahara, et al., 1999, Crosby, et al., 2000, Fujiyama, et al., 2003, 
Vasa, et al., 2001, Yoon, et al., 2005) Recent studies suggested that circulating EPC can home 
to site of tissue ischemia and injury, express endothelial antigens and play a significant role 
in new blood vessels formation and re-endothelialization (Asahara, et al., 1999, Crosby, et 
al., 2000, Fujiyama, et al., 2003, Vasa, et al., 2001). Normal adults have a small amount of 
circulating EPC in the peripheral blood (Choi, et al., 2004). In response to cytokine 
stimulation, ischemic insult, drugs, and under the influence of other pathological conditions, 
these cells are mobilized from the bone marrow (Asahara, et al., 1999, Choi, et al., 2004, 
Dimmeler, et al., 2001).  For example, numbers and angiogenic functions of EPC have been 
reported to be reduced in patients with risk factors for coronary artery disease (Vasa, et al., 
2001), 10, chronic renal failure (Choi, et al., 2004), older age (Scheubel, et al., 2003) and type II 
diabetics (Tepper, et al., 2002).  In contrast, limb ischemia (Asahara, et al., 1999), acute 
myocardial infarction (Shintani, et al., 2001) and HMG-CoA reductase inhibitors (statins) 
(Dimmeler, et al., 2001) were associated with increased EPC in the circulation and better 
angiogenic potential.  EPC accelerate re-endothelialization and improve vascular healing14.  
A reduction of their numbers and impaired function have been correlated with 
inflammatory states, adverse vascular events and death  (George, et al., 2003, Lambiase, et 
al., 2004, Ruel, et al., 2005). The exact mechanism of EPCs-mediated neovascularization is 
unknown, and possibly the EPCs differentiate into EC, or by paracrine mechanisms via 
growth factors secretion. (Smadja, et al., 2007) There are limits of the EPCs clinical 
application. (Choi, et al., 2004, Kawamoto and Asahara, 2007) Amount of available EPCs is 
restricted, so large blood sample is required for cell preparation.  
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Fig. 1. Characterization of cultured EPC by direct fluorescent staining. A) Early EPC after a 
few days in culture, adherent cells are stained with (Dil)-labeled acetylated low-density 
lipoprotein (DiLDL, red) and B) Lectin staining is performed by incubation with fluorescein 
isocyanate (FITC, green)-labeled Ulex europaeus agglutinin-I. C) Nuclei are stained with 
Hoechst (blue) and typical merge image demonstrates dual stained cells positive for both 
DiLDL and lectin are considered EPC (Dimmeler, et al., 2001) (10X original magnification). 
After staining, samples are viewed with an inverted fluorescent microscope. D) After many 
days in culture some late EPC can adopt new phenotype from small spindle-like to large, 
round and flat cells characteristic of mature endothelial cells (10X original magnification). 
Dr Noiseux, unpublished data. 
3.4 Mesenchymal Stem Cells (MSC) 
Adult MSC are a population of stromal cells isolated from bone marrow-derived stem cells 
(BMSC) (Barbash, et al., 2003, Strauer, et al., 2002, Toma, et al., 2002).  MSC have been 
isolated from many species including humans, and are present at a concentration several 
fold lower than their hematopoietic counterparts.  MSC are present at a concentration 
several fold lower than their hematopoietic counterparts, representing approximatively 
0.001-0.01% of the total nucleated marrow cell population. (Jain, et al., 2005, Meirelles Lda 
and Nardi, 2003) MSC are separated from other cells in culture by their preferential 
attachment to plastic surfaces (Colter, et al., 2000, Colter, et al., 2001, Meirelles Lda and 
Nardi, 2003).  In their undifferentiated state, MSC do not express hematopoietic or 
endothelial cell surface markers (Annabi, et al., 2003, Colter, et al., 2000, Mangi, et al., 2003, 
Meirelles Lda and Nardi, 2003, Minguell, et al., 2001, Peister, et al., 2004) such as CD14, 
CD31, CD34, CD45, but may express CD-117 (c-kit) and the majority express CD29, CD44, 
CD90, and Sca-1 (Annabi, et al., 2003, Colter, et al., 2000, Mangi, et al., 2003, Meirelles Lda 
and Nardi, 2003, Minguell, et al., 2001, Peister, et al., 2004, Pittenger and Martin, 2004). MSC 
are identified by their specific antigens (SH2, SH3, SH4, STRO-1) and adhesion molecules 
(ALCAM, CD44). (Jain, et al., 2005) MSC are easily expandable in culture without losing 
their differentiation potential (Meirelles Lda and Nardi, 2003), and they constitute an 
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unlimited pool of transplantable cells, Fig. 2.  MSC fulfilled the stem cells criteria including 
self-renewing cell division and potential for differentiation (Verfaillie, et al., 2002). MSC are 
multipotent (Grove, et al., 2004), and can differentiate into multiple lineages (Grove, et al., 
2004, Mackay, et al., 1998, Meirelles Lda and Nardi, 2003, Pittenger, et al., 1999, Song and 
Tuan, 2004), including fibroblasts, osteoblasts (Liu, et al., 2001), chondroblasts and 
adipocytes.  Differentiation of MSC to cardiomyocyte-like cells has been observed in vitro 
under specific conditions (Makino, et al., 1999, Rangappa, et al., 2003, Tomita, et al., 1999), 
and in vivo after injection into the myocardium (Dai, et al., 2005, Saito, et al., 2002, Shake, et 
al., 2002, Toma, et al., 2002, Tomita, et al., 1999, Wang, et al., 2000). 
 
 
Fig. 2. A) MSC were retrovirally transduced to express GFP (Noiseux, et al., 2006), image 
under inverted fluorescent microscope. B) MSC were injected into ischemic heart in a mouse 
model of acute MI. GFP immunostaining (green) was used for tracking the implanted cells 
at 3 days post-MI, and cardiomyocytes were labeled in red by immunostaining for cardiac 
alpha-sarcomeric actin, and nuclei are identified by Hoechst staining (blue). C) MSC were 
stained in red by immonostaining for GFP 3 days after MI, demonstrating massive 
engraftment in the infarcted area. D) MSC were retrovirally transduced to express LacZ 
gene (nuclear localizating sequence), image under light microscope after X-gal staining 
demonstrating blue nuclei. E) Thick section of rat infarcted heart after X-gal staining 
demonstrating engraftment of MSC expressing LacZ (bleu) in the infarct border zone at the 
level of the papillary muscles. F) Same as in E, but in the apical segment of the left ventricle. 
10X original magnification in A and B, 20X original magnification in B and C. Dr Noiseux, 
unpublished data. 
MSC are known to secrete a wide spectrum of biologically active factors and 
angiogenic/arteriogenic cytokines (Heil, et al., 2004, Kamihata, et al., 2001, Kinnaird, et al., 
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2004, Kinnaird, et al., 2004, Kinnaird, et al., 2004) that can be found in the culture-
conditioned medium (MSC-CM) (Heil, et al., 2004, Kamihata, et al., 2001, Kinnaird, et al., 
2004, Kinnaird, et al., 2004, Kinnaird, et al., 2004), see Fig. 3.  Under hypoxic culture 
conditions, the expression of several factors is significantly up-regulated (Gnecchi, et al., 
2005, Gnecchi, et al., 2006, Kinnaird, et al., 2004, Noiseux N, 2004, Noiseux N, 2004).  MSC 
implantation into the injured heart has been associated with improvement of cardiac 
performance and repair in animal studies and clinical trials. Because myocardial infarction 
leads to permanent loss of tissue with subsequent impaired function, the reports 
highlighting the capacity of MSC to differentiate into new cardiomyocytes have prompted 
new perspectives in the treatment of cardiovascular diseases using stem cell transplantation. 
Among adult stem cells, MSC possess unique properties that make them eligible for 
convenient and highly effective cell therapy (Jain, et al., 2005).  MSC are particularly suitable 
for cellular therapy because of their multipotency, low immunogenicity, amenability to ex 
vivo expansion, and genetic modification. However, a recent study by Vulliet et al. raised 
concerns with the use of MSC, and their findings showed acute myocardial ischemia and 
sub-acute myocardial micro-infarction following intra-coronary injection of MSC into 
ischemic dog hearts due to the formation of small capillary emboli (Vulliet, et al., 2004). 
 
 
Fig. 3. Human MSC express genes encoding several cytokines and growth factors that are 
released in the MSC-conditioned medium. Hypoxic culture condition alters the production 
of several factors. Protein arrays from RayBiotech inc. allow the detection of several proteins 
simultaneously. Dr Noiseux, unpublished data. 
3.5 Cardiac resident stem cells 
Recently identified by Hierlihy and colleagues in the adult heart, these cardiac stem cell-like 
populations were identified based on their specific ability to efflux Hoechst dye (Hierlihy, et 
al., 2002). These progenitor cells, expressing c-kit, are capable of differentiation into 
cardiomyocytes and/or vascular tissue. They are self-renewing, clonogenic, and multipotent 
(Bearzi, et al., 2007).  Recent studies have suggested that the heart has an inherent ability to 
replace its parenchymal cells continuously by these resident stem cells (Braun and Martire, 
2007). These observations suggest the capacity of adult myocardium to maintain 
physiological homeostasis, at least partially, through resident cardiac stem cells (Liao, et al., 
2007). The origin of these cardiac stem cells is unclear.  These cells could either constitute the 
remaining endogeneous cardiac stem cells dormant in the myocardium or alternatively, cells 
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that have homed to the heart from another organ (maybe the bone marrow) or in response 
from injury (Lyngbaek, et al., 2007).  These cells can be clonally expanded in vitro from an 
endomyocardial biopsy and be used for cardiac repair. 
4. Insights on mechanisms of action and fate of the implanted cells 
Over the last several years, there has been a surge of data detailing the use of cell-based 
therapies for post-MI treatment. Stem cells implantation has been shown to prevent 
deleterious remodeling and improve recovery of infarcted myocardium by cytoprotective 
effects, myogenesis and angiogenesis (Dai, et al., 2005, Davani, et al., 2003, Dowell, et al., 
2003, Kocher, et al., 2001, Mangi, et al., 2003, Min, et al., 2002, Orlic, et al., 2002, Orlic, et al., 
2001, 2003, Orlic, et al., 2001, Orlic, et al., 2001, Pittenger and Martin, 2004, Shake, et al., 2002, 
Strauer, et al., 2002, Tomita, et al., 1999, Tomita, et al., 2002, Wang, et al., 2001, Wollert and 
Drexler, 2005). The ultimate goal for cell therapy is the stem cell engraftment into the 
damaged heart and, ultimately, differentiation into new functional cardiomyocytes, vascular 
smooth muscle and endothelial cells. Although differentiation of stem cells into 
cardiomyocytes has been observed, there is much debate over the frequency of this 
phenomenon. Recent work has questioned the ability of stem cells to generate new 
cardiomyocytes. (Laflamme, et al., 2007, Murry, et al., 2004, Noiseux, et al., 2006) It remains 
unclear whether the beneficial effect results as a direct consequence of the transplanted cells 
participating and integrating in a functional syncytium with the host myocardium, or 
alternatively if the cells could benefit cardiac function without directly contributing to 
contraction (Dowell, et al., 2003). This indirect effect may be attributed to secretion of 
biologically active factors (Nguyen, et al., 2010) that could enhance the angiogenic process 
(Dowell, et al., 2003, Timmermans, et al., 2003), protect cardiomyocytes from apoptosis and 
induce proliferation, improve heart function with inotropic properties, or recruit resident 
cardiac stem cells (Wollert and Drexler, 2005). Implanted stem cells may also fuse with the 
native dysfunctional myocytes to augment function. (Noiseux, et al., 2006, Nygren, et al., 
2004, Ying, et al., 2002) Indeed, mechanistic underpinnings of stem cell therapy appear to be 
far more complex that formerly anticipated, such indirect effects are referred to paracrine 
action, Fig. 4. Interestingly, while only few groups have observed differentiation of BMSC 
into cardiomyocytes, most groups have reported a beneficial effect on post-MI remodeling 
and cardiac functional recovery (Liao, et al., 2007). As such, these data are certainly 
encouraging, given the improvement in objective measures such as infarct size and 
contractility. However, they are also disappointing, since they fail to demonstrate cardiac 
differentiation.  
The mechanisms by which stem cells can repair damaged myocardium or lead to 
improvement in cardiac function are still largely unknown.  However, the foremost 
apparent and proposed pathways are: a) direct or indirect improvement in 
neovascularization, i.e., vasculogenesis, angiogenesis and arteriogenesis; and b) 
differentiation/fusion into cardiomyocytes and formation of regenerated myocardial tissue 
(Kocher, et al., 2007). To which extent these different mechanisms of action are involved 
may critically depend on the cell type and the clinical setting, such as acute versus chronic 
ischemic injury (Kocher, et al., 2007).  For example, in patients presenting acute MI, stem cell 
transplantation is thought to significantly improve post-MI ventricular remodeling and 
function through enhanced neovascularization and reduced cardiomyocytes apoptosis, 
irrespective of long-term engraftment and trans-differentiation.  On the other hand, these  
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Fig. 4. Working hypothesis for mechanism of stem cell transplantation for the treatment of 
ischemic cardiomyopathy. Stem and progenitor cell transplantation can have a favorable 
impact on tissue perfusion and contractile performance by promoting vascularization and 
myocytes formation. Improved vascularization may facilitate beneficial effects in the 
myocyte compartment. Adapted from  (Wollert and Drexler, 2005).  
later mechanisms may have little or no benefit in patients with long established scars, apart 
from the functional rescue of hibernating cardiomyocytes. Virtually all currently available 
mechanistic insights have come from pre-clinical studies in animal models, whereas the 
human experience is rather limited (Laflamme, et al., 2007). 
4.1 Stem cells (Trans)differentiation 
The foremost purpose of cell-based therapies remains the regeneration of lost cardiac cells 
via stem cells (trans)differentiation into new contractile cardiomyocytes. (Liao, et al., 2007) 
Crucial proof-of-principle data in support of this contention were provided by early animal 
studies with transplantation of fetal and neonatal cardiomyocytes following acute MI 
(Laflamme, et al., 2007). Implanted myocytes formed stable intra-cardiac grafts and resulted 
in improved left ventricular function (Jia, et al., 1997, Li, et al., 1996, Li, et al., 1997, Sakai, et 
al., 1999, Scorsin, et al., 2000). Skeletal muscle satellite cells (referred commonly as 
myoblasts) have also been exhaustively examined as candidate cells for cardiac repair. 
Unlike native cardiomyocytes which form an electrical syncytium via gap junction coupling, 
implanted myoblasts are isolated and do not contract in synchrony with the host 
myocardium (Leobon, et al., 2003). Embryonic stem cells (ESC) are unambiguously 
cardiogenic cell type, capable of differentiating into cells with ventricular, atrial and 
pacemaker/conduction system phenotypes (He, et al., 2003, Kehat, et al., 2001). 
Cardiomyocytes derived from ESC are able to form stable intra-cardiac implant, and 
provide functional benefit in murine experimental infarct models (Hodgson, et al., 2004, 
Singla, et al., 2006). 
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Orlic et al were among the first to demonstrate in a mice model of AMI that bone marrow 
could provide an extra-cardiac source of progenitor cells with the ability to differentiate into 
cardiomyocytes and restore cardiac function (Orlic, et al., 2001, Orlic, et al., 2001, Orlic, et al., 
2001). Studies in several species demonstrated that BMSC are stem cells found in various 
mesenchymal tissues, and precursors of peripheral tissue such as the heart muscle (Strauer 
and Kornowski, 2003). Cardiogenic potential has also been demonstrated for a surprisingly 
high number of adult progenitor cell types, including HSC, MSC, circulating EPC, resident 
cardiac progenitor cells, adipose-derived stem cells and others (Badorff, et al., 2003, 
Beltrami, et al., 2003, Laflamme, et al., 2007, Oh, et al., 2003, Planat-Benard, et al., 2004, 
Toma, et al., 2002). When BMSC are transplanted into an ischemic heart, they can express 
the cardiac specific markers troponin I and cardiac myosin, suggesting transformation into 
functional cardiomyocytes (Grigoropoulos and Mathur, 2006, Kajstura, et al., 2005, Yoon, et 
al., 2008).   
Using genetic markers (e.g., Y chromosome) and/or labeled fluorescent dyes (e.g., Green 
fluorescent protein GFP), many groups reported the transdifferentiation of bone marrow-
derived HSC into cardiomyocytes following implantation into ischemic heart (Jackson, et al., 
2001, Liao, et al., 2007, Orlic, et al., 2001, Orlic, et al., 2001). However, these early 
observations have been called into question by others, who failed to identify similar 
cardiomyocytes derived from implanted stem cells (Balsam, et al., 2004, Murry, et al., 2004).  
Further experimental studies addressing the capacity of transplanted BMSC to differentiate 
into the cardiomyogenic lineage yielded conflicting results (Anversa, et al., 2007, Dimmeler, 
et al., 2008, Murry, et al., 2004).   
4.2 Cellular fusion 
Despite the initially observation that implanted HSC could generate new cardiomyocytes in 
the infarcted heart, several groups have subsequently revisited this hypothesis of stem cells 
differentiation (Laflamme and Murry, 2005, Laflamme, et al., 2007, Murry, et al., 2004, 
Noiseux, et al., 2006). Using state-of-the-art techniques and genetic markers, it has been 
suggested that rarely cardiomyocytes would display lineage markers of the transplanted 
stem cells, but that myocardial cells were derived from the fusion of implanted stem cells 
with damaged host cardiomyocytes (Alvarez-Dolado, et al., 2003, Laflamme, et al., 2007, 
Murry, et al., 2004, Nygren, et al., 2004). Fusion of transplanted stem cells with resident 
cardiomyocytes has been offered as an alternative for the previous claims of 
transdifferentiation (Alvarez-Dolado, et al., 2003, Balsam, et al., 2004, Murry, et al., 2004, 
Noiseux, et al., 2006, Nygren, et al., 2004, Wollert, 2008).  Fused implanted cells may adopt 
phenotype of recipient cells, and without detailed genetic analysis, might be falsely 
interpreted as differentiation (Terada, et al., 2002). Fusion of BMSC with purkinje neurons, 
hepatocytes and cardiomyocytes has been reported by Alvarez-Dolado et al in 2003 
(Alvarez-Dolado, et al., 2003). Using different genetic markers to track the fate of 
transplanted cells, fusion with recipient cardiomyocytes has been also reported for 
peripheral blood CD34+ cells (Zhang, et al., 2004), hematopoietic stem cells (Murry, et al., 
2004, Nygren, et al., 2004), cardiac progenitor cells (Oh, et al., 2003), and skeletal muscle cells 
(Reinecke, et al., 2004). 
It is possible that many examples of putative stem cell plasticity reported in the literature 
are actually due to transplanted cells fusing with a different tissue type, followed by 
reprogramming of the donor and recipient cell genome (Vassilopoulos and Russell, 2003). 
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To address the issue of cellular fusion, it is imperative to use a method that allows the 
tracking of the implanted cells, but also a genetic marker that can be triggered exclusively by 
fusion event. A well-validated technique suitable for this purpose relies on the use of 
Cre/LoxP system. Using a model of AMI in transgenic mice, we previously demonstrated 
that transplanted MSC could fuse with recipient cardiomyocytes in the infarcted area 
(Noiseux, et al., 2006). MSC from wild type C57BL/6 mice were retro-virally transduced to 
express GFP as reporter gene and Cre recombinase. These MSC were transplanted into 
infarcted hearts of histocompatible R26R mice (similar C57BL/6 genetic background). In 
these transgenic mice, a loxP-flanked stop sequence is present 5’ of the LacZ expression 
cassette to prevent transcriptional read-through until selective excision by Cre mediated 
recombination from implanted MSC (Soriano, 1999). Thus, the LacZ gene is expressed 
exclusively after a donor MSC expressing Cre fuses with a recipient cell from the R26R mice.  
Consequently, X-gal staining is used to detect cellular fusion events (Alvarez-Dolado, et al., 
2003, Nygren, et al., 2004) As early as 3 days following MSC injection into the ischemic 
heart, we observed cellular fusion with individual blue cells having typical cardiomyocyte 
morphology.  Interestingly, the majority of the fusion events with LacZ+ cells were detected 
within the infarct border zone, in areas with viable cardiomyocytes. 
4.3 Indirect and paracrine effects 
Despite the lack of significant myocardial regeneration by implanted stem cells through 
differentiation into new cardiomyocytes, numerous studies reported that cardiac function 
can be improved by cell therapy, suggesting further evidence for a non-myogenic pathway 
of cardiac repair (Laflamme, et al., 2007). Regardless of the mechanism responsible for the 
beneficial effects of stem cell therapy on post-MI, cardiac function improvement remains 
disproportionate to the degree of cardiomyogenic differentiation. (Liao, et al., 2007, Noiseux, 
et al., 2006) Indeed, the variable observations relating to cell transdifferentiation and fusion, 
as well as transient cell retention and survival in the ischemic heart (Noiseux, et al., 2006), 
have prompted a rethinking of the mechanisms that account for the functional benefits of 
cell therapy in cardiac repair (Psaltis, et al., 2008). It has been proposed that stem cell 
transplantation may improve myocardial function recovery predominantly by facilitating 
endogenous repair mechanisms, rather than through direct regeneration of lost 
cardiomyocytes and vascular cells. Thus, it is possible that implanted cells could secrete 
bioactive factors which may stimulate angiogenesis, suppress apoptosis of cardiomyocytes, 
increase efficiency of cardiomyocyte metabolism, improve inotropy of survival myocytes, 
modulate interstitial matrix composition and remodeling, and maybe even recruit cardiac 
resident stem cells (Gnecchi, et al., 2006, Kamihata, et al., 2001, Kinnaird, et al., 2004, 
Noiseux, et al., 2006, Wollert, 2008). The fact that it is possible to improve the heart’s 
function without remuscularizing the infarct is already known from numerous 
pharmacological studies, e.g. with beta–adrenergic blocker or angiotensin-converting 
enzyme inhibitors and this has resulted in a search for other potential mechanisms of action 
(Laflamme, et al., 2007).  
MSC are known to secrete a wide spectrum of biologically active factors, (Heil, et al., 2004, 
Kamihata, et al., 2001, Kinnaird, et al., 2004, Kinnaird, et al., 2004, Kinnaird, et al., 2004) and 
under hypoxic culture condition and serum starvation, conditions that mimic myocardial 
infarct, the expression of several factors is significantly up-regulated (Gnecchi, et al., 2005, 
Gnecchi, et al., 2006, Kinnaird, et al., 2004, Noiseux N, 2004, Noiseux N, 2004). These growth 
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factors and cytokines are released in the culture medium (MSC-conditioned medium, MSC-
CM), and can be concentrated and use therapeutically. We previously reported that 
transplantation of MSC into ischemic myocardium improved cardiac function recovery and 
repair as early as 72 hours, which is too early to be explained solely by myocardial 
regeneration from MSC (Gnecchi, et al., 2005, Gnecchi, et al., 2006, Noiseux, et al., 2006). 
Transplanted cells were found within the infarcted myocardium (detection of MSC by GFP 
immunoreactivity). Early massive engraftment was observed at 3 days, but the number of 
implanted MSC decreased significantly over time, and by 28 days post-MI very few cells 
remained. Since such an early recovery cannot be explained entirely by de novo myogenesis, 
we proposed that MSC could achieve cardioprotection by indirect effects, through paracrine 
mediators, rather than cardiac regeneration. Furthermore, to investigate how MSC could 
achieve protection of the ischemic myocardium by paracrine mediators and indirect effects, 
we demonstrated that MSC-CM reduced hypoxia-induced apoptosis, and also triggered 
vigorous spontaneous contraction of isolated hypoxic adult rat cardiomyocytes in vitro, 
suggesting the presence of anti-apoptotic and inotropic factors (Gnecchi, et al., 2006). 
Moreover, when injected directly into infarcted rat hearts, the MSC-CM limited infarct size 
as early as 72 hours and improved ventricular function (Gnecchi, et al., 2005, Gnecchi, et al., 
2006) at levels comparable to those observed following MSC transplantation. These 
remarkable data strongly support the concept that the effects observed after intramyocardial 
injection of MSC into infarcted hearts are to a great extent attributable to paracrine 
protection and indirect effects on ischemic myocardium. 
Recently, we investigated the effects of MSC-secreted growth factors on extent of early 
recovery from MI in a large animal pre-clinical model (Nguyen, et al., 2010).  Swine 
subjected to acute MI by temporary balloon occlusion of the left anterior descending 
coronary artery using percutaneous techniques received intra-coronary injection of either 
concentrated MSC-derived growth factors or control medium.  Treatment with MSC-
derived factors significantly reduced cardiac tropinin-T elevation, and improved 
echocardiographic parameters, including fractional area shortening, stroke volume, and 
cardiac output.  Quantitative evaluation of fibrosis by Verhoff staining revealed a reduction 
of the fibrotic area in the infracted zone at 7 days. Similarly, Masson’s trichrome staining 
revealed reduced myocardial damage as demonstrated by areas of relatively preserved 
myocardium in the infracted area.  TUNEL assay demonstrated less cardiomyocyte 
apoptosis. Protein array detected the presence of angiogenic (VEGF, endothelin, epiregulin), 
anti-apoptic (Galectin-3, Smad-5, sRFP-1), and anti-remodeling factors (TIMP). RT-PCR 
confirmed the expression of these factors. In summary, a single intra-coronary injection of 
concentrated biologically active factors secreted by MSC could achieve early protection of 
ischemic myocardium, improve cardiac repair, and partially preserve contractility.  MSC-
derived growth factors injection (rather than MSC themselves) should be evaluated as a 
novel therapy to treat ischemic heart disease, many practical and technical issues of cell 
therapy. 
4.4 Healing response, inflammation and tissue perfusion 
Following myocardial infarct, inflammation and cytokine production regulate myocytes 
survival/apoptosis, and trigger additional cellular responses, contributing to the healing 
and remodeling of the injured tissue, which may ultimately influence clinical outcome 
(Nian, et al., 2004). The immune system plays a crucial role during the acute phase of MI 
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and this constitutes a most appropriate timing where any immunomodulatory effects 
following stem cell implantation could exert their effects (Laflamme, et al., 2007). An 
adequate microenvironment supporting nutrient delivery and waste removal is necessary to 
sustain survival, growth and possibly differentiation of the transplanted cells (Timmermans, 
et al., 2003). Therefore, concurrent revascularization must keep pace with cell repopulation 
of the infarcted tissue (Luttun and Carmeliet, 2003). Transplanted cells may act in an 
indirect supportive role, optimizing the milieu for host vasculature and cells to respond to 
ischemia and healing. (Gnecchi, et al., 2005, Kinnaird, et al., 2004, Kinnaird, et al., 2004, 
Noiseux N, 2004) Normal growth and ultimate stem cell fate depend on engraftment in an 
appropriate “niche”.  Thus, it appears that the fate of stem cells is determined by the 
environment in which they are engrafted rather than by an intrinsically programmed fate, 
but the mechanisms explaining how the local milieu influences stem cell differentiation are 
yet to be characterized (Strauer and Kornowski, 2003).  Importantly, an angiogenic response 
has been observed in many studies following cell transplantation (Dowell, et al., 2003).  
Much attention has been focused on the direct consequence of cell-based therapy by the 
renewal of lost parenchymal cells, but restoration of the extra-cellular matrix and vascular 
supply are also important issues since both components are essential for structural and 
functional support of the surviving cardiomyocytes (Timmermans, et al., 2003) in the 
ischemic myocardium.  It is also important to consider other potential mechanisms by 
which transplanted cells could benefit cardiac function without directly contributing to 
systolic contraction. Blood vessel formation in the heart proceeds mainly through 2 
mechanisms: angiogenesis and arteriogenesis. Arteriogenesis is by far the most efficient 
adaptative mechanism for survival of ischemic organs because of its ability to conduct 
relatively large blood flow (Buschmann and Schaper, 1999).  Angiogenesis and 
arteriogenesis are complex processes sharing several common mechanisms of action, 
growth factors and cytokines dependency (Buschmann and Schaper, 1999).  Many of these 
cytokines act not only in a co-ordinated time- and concentration-dependent manner, but 
one cytokine may potentiate (or inhibit) the effect of another (Kinnaird, et al., 2004), and 
the complexity of the process of collateral formation has led to speculate that multiple 
factor strategies could be used therapeutically to modulate vessel formation (Kinnaird, et 
al., 2003). The recruitment of monocytes that differentiate into macrophages and produce 
abundant angiogenic growth factors such as VEGF, NO, monocyte chemoatractant 
protein-1 (MCP-1) and other cytokines, is also essential and ultimately leads to 
endothelial and smooth muscle cell proliferation, migration, vessel remodeling and extra-
cellular matrix synthesis.   
The observation that BMSC contain a subpopulation of endothelial progenitor cells with the 
potential for angiogenesis suggests that these cells may contribute to cardiac repair by 
enhancing the local blood supply in ischemic myocardium (Grigoropoulos and Mathur, 
2006). Some reports have suggested that MSC implantation into ischemic tissue promote 
collaterals development through paracrine mechanisms, but not through direct cell 
incorporation into growing vasculature (Dowell, et al., 2003, Fuchs, et al., 2001, Heil, et al., 
2004, Hirata, et al., 2003, Kamihata, et al., 2001, Kinnaird, et al., 2004, Kinnaird, et al., 2004, 
Kinnaird, et al., 2003, Kobayashi, et al., 2000, Li, et al., 2002, Mangi, et al., 2003, Strauer, et al., 
2002, Ziegelhoeffer, et al., 2004).  MSC express genes encoding a broad spectrum of 
cytokines with angiogenic properties including VEGF, HGF, FGF, MCP-1, PGF, IL-1 and IL-
6, SDF-1, MMP-9 (Kinnaird, et al., 2004, Kinnaird, et al., 2004, Timmermans, et al., 2003).  
These cytokines can be found in the media of cultured cells, and have all individually been 
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shown to have positive effects on experimental blood flow recovery (Buschmann, et al., 
2003, Heil, et al., 2004, Kinnaird, et al., 2004, Kinnaird, et al., 2004, Kinnaird, et al., 2004, 
Timmermans, et al., 2003).  Moreover, media collected from MSC cultures (MSC-derived 
conditioned medium, MSC-CM) promote in vitro proliferation and migration of endothelial 
cells (EC) and vascular smooth muscle cells (VSMC), and enhance in vivo collateral blood 
flow recovery when injected into ischemic hindlimb (Kinnaird, et al., 2004, Kinnaird, et al., 
2004, Timmermans, et al., 2003).  It is possible that neovascularization by cell therapy is 
leading to enhanced blood supply in the peri-infarct region and thereby promoting salvage 
of stunned, hibernating, or otherwise susceptible cardiomyocytes (Laflamme, et al., 2007). 
Controversy persists regarding the exact mechanisms through which cell transplantation 
may enhance repair and collateral development in ischemic tissue (Kinnaird, et al., 2004).  
5. Lessons from early clinical trials: feasibility, efficacy and safety  
Over the past few years, cell therapy has emerged as a potential new treatment of a variety 
of cardiac diseases, including AMI, refractory angina, and chronic heart failure. (Menasche, 
2009) A variety of cell types have been tested experimentally, each of them being usually 
recognized by its beneficial "regeneration" potential. This has led to a flurry of clinical trials 
entailing the use of skeletal myoblasts or bone marrow-derived cells either unfractionated or 
enriched in progenitor subpopulations. Following acute MI, the observation that 
mobilization of BMSC occurs naturally to heal the myocardium led several groups to 
investigate their potential for cardiac repair (Shintani, et al., 2001). In patients with recent 
MI, Strauer et al demonstrated that IC administration of unselected BMSC was safe and 
associated with improved cardiac performance (Strauer, et al., 2002). In the same way, 
Zeiher et al reported that IC administration of BM progenitors after MI improved cardiac 
performance and enhanced the myocardial perfusion of the infarcted myocardium up to 1 
year of follow-up (Assmus, et al., 2002, Britten, et al., 2003, Schachinger, et al., 2004). The 
landmark multi-center placebo-controlled REPAIR-AMI trial showed also a higher increase 
in the LVEF in the cell treated group compared to controls (Schachinger, et al., 2006), this 
effect was sustained up to 2 years and was associated with a significant reduction in the 
MACE rate (Assmus, et al., 2010). Recently, the FINCELL trial showed also that following 
acute MI, BMSC therapy significantly improved the LVEF recovery in treated patients as 
compared to controls (Huikuri, et al., 2008). Interestingly the randomized “BOOST” trial 
showed an improvement in the cardiac function following IC injection of autologous BMSC 
without adverse effect. Furthermore, this beneficial effect was sustained at 6 months 
(Wollert, et al., 2004) and 1 year of follow-up (Schaefer, et al., 2006), but not at 18 months15 
raising questions about the potential transient effect of heterogeneous cells on cardiac repair 
(Meyer, et al., 2006).  
Although many trials demonstrated a slight benefit on cardiac functional recovery, recent 
studies have yielded disparate results (Janssens, et al., 2006, Lunde, et al., 2006, Tendera, et 
al., 2009). In the randomized ASTAMI trial, the use of IC unselected BMSC following acute 
MI failed to demonstrate at 6 months any improvement in LVEF (Lunde, et al., 2006). 
Similarly, Janssens et al reported no significant difference in overall LVEF at 4 months, but 
showed a decreased infarct size and better regional function in cell-treated patients 
(Janssens, et al., 2006). Moreover, the REGENT acute MI trial failed to show any significant 
improvement in the LVEF, LVEDV and LVESV at 6 months in patients treated with 
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unselected mononuclear cells or selected CD34+ CXCR4+ cells as compared to controls. 
Finally, Lunde et al (Lunde, et al., 2008) failed to show any improvement in the LV function 
in patients with anterior MI treated with BMSC. 
In the most recently published SCAMI (Wohrle, et al., 2010) (Stem Cell therapy in patients 
with Acute Myocardial Infarction) study which used serial MRI for assessing results in 42 
patients, of whom 29 were allocated to the treated arm), there was no either evidence for a 
positive effect of intracoronarily infused stem cells treatment versus placebo with regard to 
LVEF, volumes or infarct size. In this study, the centrifugation technique used for collecting 
mononuclear cells was similar to that used in the REPAIR-MI trial and a greater number of 
cells (381×106 versus 240×106 in REPAIR-MI) was injected at was has been identified as the 
optimal time point, i.e., at a median of 6.1 days after infarction, a noticeable difference 
between these two conflicting trials being the longer interval between symptom onset and 
revascularization in the SCAMI patients (14.3 hours versus 4.5 hours in REPAIRMI). 
However, a salient feature of the SCAMI protocol has been the rigorousness of the blinding 
since the control preparation consisted of autologous erythrocytes, which made the placebo 
syringes indistinguishable from those of the treated group), the design of the SCAMI trial 
strongly validates its conclusions. 
Put altogether, these data clearly show that the potential benefit of bone marrow-derived 
stem cell therapy shortly after AMI still remains conflicting and the major lesson drawn 
from this first wave of clinical studies is therefore that there is a real need for a large, 
adequately powered trial incorporating some of the key findings of the previous studies 
regarding cell preparation, dosing and timing of delivery and focusing on clinically relevant 
“hard” end points such as mortality, re-infarction and heart failure. Four recent meta-
analyses of BMC in the setting of acute MI incorporating 5, 10, 13, and 18 trials, helped to 
position results of individual trials into perspective (Abdel-Latif, et al., 2007, Hristov, et al., 
2006, Lipinski, et al., 2007, Martin-Rendon, et al., 2008). Overall, results of these randomized 
placebo-controlled trials and cohort studies are promising in that they demonstrate 
feasibility, safety, and a slight but positive improved LVEF of 3.66%, a reduced infarct scar 
size of -5.49% and a reduced LVESV volume of -4.80 ml (Abdel-Latif, et al., 2007). Thus, 
available evidence suggests that BMSC transplantation is associated with modest 
improvement in physiologic and anatomic parameters in patients with both acute MI and 
chronic ischemic cardiomyopathy, but above and beyond conventional therapy (Abdel-
Latif, et al., 2007) and could leads to significant and longstanding reduction in the mortality 
of patients after acute MI as demonstrated in the Balance study (Martin-Rendon, et al., 
2008). Therefore, therapy with stem cells appears to be safe, but well-designed double-
blinded and randomized studies are clearly needed to confirm promising findings from 
early studies.    
To date, fewer randomized trials of IC trans-catheter transplantation of BMSC have been 
performed in the setting of chronic coronary artery disease and chronic heart failure 
(Assmus, et al., 2007, Erbs, et al., 2005, Tse, et al., 2007). Nonetheless, the results are similar 
to those in patients with acute MI, showing an improvement in LV function, perfusion, and 
relief of angina pectoris (Losordo, et al., 2007, van Ramshorst, et al., 2009). Assmus et al. 
reported a registry of 121 consecutive patients with chronic ischemic heart disease treated 
with intracoronary infusion of BMC (Assmus, et al., 2007). Importantly, they demonstrated 
that infusion of high number of colony forming cells is associated with a significantly lower 
mortality during further follow-up (Assmus, et al., 2007). Recently, Strauer et al. (Strauer, et 
al., 2010) reported in patients with chronic ischemic cardiomyopathy treated with 
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intracoronary BMSC therapy a significant improvement in the LVEF with a significant 
decrease in long-term mortality as compared to the control group over 3 months to 5 years 
of follow-up. These 2 studies were not blinded and randomized, and either lacked or only 
had a matched cases control groups.  
5.1 What about safety? 
As often in medicine, the hype generated by the early uncontrolled and small-sized clinical 
trials has been dampened by the marginally successful outcomes of the subsequent, more 
rigorously conducted randomized trials. (Menasche, 2009) Although they may have failed or 
succeed to achieve their primary functional end points, these trials have been positive in the 
sense that they have allowed to identify a major key issue regarding the safety and 
feasibility of this therapy. Cardiac cell therapy is overall safe in surgical studies where cells 
have been injected with hand-held syringes directly in the myocardium, no bleeding 
complications have been reported. Catheter-based endocardial injections have been equally 
safe without an increased risk of re-infarction, stent thrombosis or in-stent restenosis  
(Zhang, et al., 2009). Although the use of the intramyocardial injection of myoblasts was 
associated with the occurrence of sustained ventricular arrhythmias  (Menasche, 2008), none 
of the trials testing the BMNC has reported an  increased incidence of malignant 
arrhythmias  (Menasche, 2011). Likewise, there has been no report of cell-derived tumor 
formation in the myocardium or elsewhere. This is clinically relevant as the longest follow-
up periods now span almost 10 years  (Menasche, 2009, Zhang, et al., 2009).  
5.2 What about used endpoints in the previous trials? 
So far, ejection fraction (EF) has usually been the gold standard for assessing outcomes in 
the first generation of clinical trials, regardless of the method on which its calculation was 
based (echocardiography, angiography, radionuclide imaging or magnetic resonance 
imaging which is likely the most reliable but may not be always possible because of a 
previously implanted ICD). There is mounting evidence that changes in EF may not be the 
most suited criteria for assessing the effects of cell therapy. Quantitative assessment of 
regional systolic function, such as echocardiographic strain rate, could be more sensitive 
than measuring global LVEF for the evaluation of cell therapy after AMI. (Wollert and 
Drexler, 2010) In trials exploring a new cell type in a limited number of patients, 
measurements in regional geometry and function with state of-the-art imaging modalities 
may be more useful than global assessments for establishing the proof of concept and 
providing mechanistic cues (Herbots, et al., 2009).   
5.3 Selected vs. unselected cells for myocardial transfer?  
There is currently uncertainty as to which of the stem cell population is most potent in 
stimulating angiogenesis and cardiac repair. Nevertheless, the use of hematopoietic 
progenitor stem cells appears to uniformly induce neovascularization that seems to be a 
prerequisite of the successful functional repair. The hematopoietic stem cells are 
characterized by the presence of the surface marker CD34. In addition, CD133 has been 
identified as a marker that is present on the stem cells that co-express not only CD34 but 
also other markers such as c-kit.  It is hypothesized that use of CD133+ cells may involve 
larger and more primitive group of stem cells than selection based only on the use of CD34+ 
marker. The use of non-homogenous or un-selected stem cells may contribute to the 
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regeneration of necrotic myocardium and blood vessels, but does not allow the 
characterization of optimal cell type for cardiac repair. Moreover, different cell types may 
compete for the engraftment in the injured myocardium (Rosenzweig, 2006). The group of 
Drexler showed that selected BMSC displayed a 7-fold higher retention in the infarcted 
myocardium, when compared to unfractionated and unselected BMSC (Hofmann, et al., 
2005). Furthermore, Stamm (Stamm, et al., 2003) used CD133+ cells for intramyocardial 
injections performed during an open-chest procedure, and observed an improvement in the 
tissue perfusion and LVEF during follow-up. Experimental studies demonstrated that 
selected, well-defined hematopoeitic stem cells contribute to cardiac repair of the acutely 
infarcted myocardium by inducing neovascularization, inhibition of apoptosis and 
cardiomyogenesis. Indeed, the hematopoietic CD133+ cells possess high engraftment, 
multipotent and angiogenic capacity, and appear to be valuable for cardiac repair in 
experimental myocardial infarction (Bhatia, 2001, Kuci, et al., 2003, Quirici, et al., 2001). 
Menasche showed in the situation of post-MI scars, transplantation of CD133+-derived 
BMSC improves cardiac function, and benefit was similar to that afforded by myogenic 
cells. (Agbulut, et al., 2004)  
Bartunek et al. tested in a phase I study the feasibility, safety and functional effects of 
intracoronary administration of selected CD133+ BMSC in patients with recent MI. 
(Bartunek, et al., 2005) They noted a significant increase of 7% in the LVEF in the treated 
group compared to 3% in controls at 4 months of follow-up. Importantly, they showed in 
cell-treated patients that improvement of the LV function was paralleled with increased 
myocardial perfusion and viability (Bartunek, et al., 2005). However, they noted in the 
treated patients an increase of coronary events with greater in-stent proliferation and larger 
luminal loss in the non-stented segments of the infarct-related artery that resulted in a 
significant decrease in pressure-derived FFR (Fractional Flow Reserve) (Mansour, et al., 
2006) mainly in early compared to late intracoronary CD133+ cells administration 
(Vanderheyden, et al., 2007). Yet, these data were obtained from retrospective analysis; they 
lack randomized controls and systematic use of intravascular ultrasound imaging to track 
changes in the vascular wall.  
5.4 The COMPARE-AMI trial 
Our group initiated the first Canadian clinical trial evaluating the intracoronary injection of 
autologous highly selected CD133+ bone marrow-derived stem cells in patients presenting 
acute MI treated by percutaneous intervention and intra-coronary stent implantation: the 
COMPARE-AMI trial (Mansour, et al., 2010, Mansour, et al., 2009). This is a randomized, 
double blind, placebo controlled study. We are investigating the safety, feasibility and 
efficacy, and the change in the coronary atherosclerotic burden progression in the treated 
artery, in addition to the change in LVEF measured by MRI. For more details on the study, 
please visit http://www.anzctr.org.au, study#ACTRN12609001045202. We published a 
preliminary safety analysis on the first twenty patients that were successfully randomized 
and treated in the COMPAREAMI trial. The mean age was 52.2±8.9 years with a 
predominance of males (90%); culprit lesion was located on the left anterior descending 
artery in 90%, and peak troponin and CKMB were 10.5±8.3 Ug/L and 341±260 U/L, 
respectively suggesting large infarct. (Mansour, et al., 2011) To date, there is no protocol-
related complication to report such as death, MI, stroke, or sustained ventricular 
arrhythmia. Re-PCI was necessary at 4 months of follow-up in three patients to treat bare-
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metal stent restenosis. These patients were asymptomatic; however, silent ischemia was 
documented in the target territory. Baseline fractional flow reserve (FFR) was significantly 
lower in the stented culprit artery compared to the non-culprit artery at baseline: 0.88±0.05 
vs 0.96±0.04, P<0.001. However, at 4 months of follow-up (n=20), no significant difference 
was found in the delta FFR compared to baseline in the culprit vs. non-culprit artery 
(−3.7%±5.4 vs −1.1%±4.6, respectively, P=0.148), suggesting no acceleration of the 
atherosclerosis by the treatment. Finally, at 4 months of follow-up, MRI assessment of the 
LVEF (n=18 patients) showed a significant improvement compared to baseline with LVEF 
51.1%±2.5 vs 41.2%±1.1, respectively (P<0.001;). This improvement was sustained at 12-
month followup (52.3% ± 2.0, P < .001 versus baseline, n = 13). Fig. 5. illustrates the 
procedure and typical results obtained in patients enrolled in our research protocol. 
 
 
Fig. 5. A) Selected CD133+ bone marrow-derived cells or placebo is injected intracoronary in 
patients participating to the COMPARE-AMI trial. B) Using a small catheter under 
fluoroscopic guidance, the cells or placebo are injected in the stented coronary artery. C) 
During injection, a balloon is occluding the coronary artery proximally. D) A representative 
left heart ventriculography showing a near complete recovery of cardiac function in a 54-
year-old man after his randomization in COMPARE-AMI trial. E) Technetium-99 m 
Sestamibi single-photon emission computed tomography (MIBI SPECT) scintigraphy 
looking at myocardial perfusion. The same patient as in D. A, B and C from Dr Noiseux and 
Dr Mansour, unpublished data. D and E, adapted from  (Mansour, et al., 2010). 
In conclusion, the findings of the present studies are as follows: i) BMC therapy after MI 
provide a faster improvement in systolic cardiac function, including LVEF, LVESV and 
LVEDV, compared with controls. These improvements were sustained after at least six 
months; ii) Statistically and clinically significant benefits were observed in the regional 
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cardiac anatomy, but these did not provide a physiological benefit; iii) In the baseline-
impaired LVEF subgroup, LVEF improved after BMC therapy compared with the control 
treatment; iv) BMC therapy was safe, but a reduction in cardiovascular events was not 
observed; v) Subgroup analyses suggested that cell infusion after AMI had a positive effect 
on LVEF. Cell infusion within 4-15 days with a higher number of CD34+ cells may have a 
beneficial impact on LVEF; and vi) Selected BMC are safe and may have a beneficial effect 
on the healing of the infarcted myocardium.   
Recently, we initiated a second study in our stem cell therapy program, looking at a 
different patient population presenting chronic ischemic cardiomyopathy associated with 
reduced LV function. IMPlantation of Autologous CD133+ sTem cells in patients undergoing 
coronary artery bypass grafting (CABG) surgery or IMPACT-CABG trial is a randomized, 
prospective, double blind, placebo-controlled phase II clinical trial designed a to assess the 
safety, feasibility and functional benefit of intramyocardial injection of autologous CD133+ 
BMSC as compared to placebo at the time of CABG surgery. The first 5 patients were treated 
in an open label fashion and received 10 millions autologous CD133+ cells with CABG. For 
more details, please visit http://clinicaltrials.gov, study #NCT01033617. To date, 7 patients 
were enrolled, and no protocol related complications were observed. Our preliminary work 
suggests the safety of CD133+ autologous cells for cardiac repair, and possibly beneficial 
effects on cardiac function are observed. 
5.5 IMPACT-CABG trial: case report, presentation of the first treated patient 
A 59 year-old male with angina at rest (CCS class 4) and congestive heart failure symptoms: 
dyspnea on slight exertion (NYHA functional class III) and edema of the lower extremities 
was referred for coronary artery bypass graft (CABG) surgery. He was an active smoker and 
known for hypertension, type II diabetes since 20 years treated with insulin and a slight 
chronic renal insufficiency (creatinine 134 umol/L, estimated glomerular filtration rate of 47 
ml/min/1.73m2). His coronary angiogram showed a left dominance system with 90% 
stenosis on the left anterior descending coronary artery (LAD), 80% on the first diagonal 
branch and 80% on the posterior descending artery (PDA). In addition, he was known to 
have a severe left ventricular (LV) dysfunction as assessed by left ventriculography (30%) 
and echocardiography (LVEF 35-40%). He consented to participate in the IMPACT-CABG 
study, a phase II clinical trial testing the safety and feasibility of selected CD133+ bone 
marrow stem cells. Pre-operative stress echocardiography and magnetic resonance imaging 
(MRI) depicted on the left ventricle necrosis of the apical segment with aneurysm, 
hypokinesia of mid and basal regions the antero-septal and antero-lateral segments, and 
akinesia of the infero-apical segments. On the morning of the surgery, the patient 
underwent bone marrow (BM) aspiration from the iliac crest under local anesthesia. Stem 
cells were prepared in the cell therapy laboratory and CD133+ cells were purified using the 
CliniMACS® CD133 Reagent System from Miltenyi Biotech Inc®. On the evening of the same 
day, the patient underwent CABG surgery and received the left internal thoracic artery on 
the LAD and a saphenous vein graft on the PDA. Immediately following distal anastomoses, 
autologous CD133+ cells (10 millions cells, 15 injection sites) were injected directly into the 
myocardium using a 26g needle in the anterior and lateral wall of the left ventricle (Figure 
6). The aortic cross-clamp time and the total cardiopulmonary bypass (CPB) time were 29 
minutes and 45 minutes respectively. The peri-operative course was uneventful without any 
in-hospital complication related to neither the research protocol nor the surgery. The patient 
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was discharged from the hospital after 7 days. At 6 months follow-up, the patient symptoms 
improved to NHYA class I and LVEF was increased to 60% assessed by echocardiography 
(Table 1). Regional motion also improved: contractility of the apical region enhanced 
significantly, and the left antero-septal segments were only slightly hypokinetic. The MRI 
study demonstrated a spectacular improvement of the perfusion in all territories with 
disappearance of the ischemia in the antero-apical and inferior territories and with mild 
 
 
Fig. 6. A) Bone marrow aspiration in the iliac crest in the IMPACT-CABG trial protocol. B) 
Bone marrow is transferred into a blood collection bag with heparin. C) After CD133+ stem 
cells isolation and selection using the CliniMACS system from Miltenyi Biotech© cells are 
transferred into 1.0 ml syringe for injection. D) Intra-operative injection of the CD133+ stem 
cells into the infarcted area and infarct border zone. Dr Noiseux, unpublished data. 
 
 Baseline 6 months post-CD133+ 
Echocardiography:   
LVEF bi plan % 41 60 
WMS  37 22 
WMSI 2.3 1.4 
 
MRI: 
  
LVEDV ml (ml/m2) 179 (107) 178 (106) 
LVESV ml (ml/m2) 111 (66) 94 (56) 
LVEF % 38 48 
LV mass gr  (gr/m2) 118 (70) 140 (83) 
Stroke volume ml 68 84
Table 1. Echocardiography and magnetic resonance imaging results at baseline and at 6 
months post CD133+ injections. LVEF: left ventricular ejection fraction; WMS: wall motion 
score; WMSI: wall motion score index (normal=1); LVEDV: left ventricular end diastolic 
volume; LVESV: left ventricular end systolic volume; MRI: magnetic resonance imaging. 
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ischemia in the antero and inferoseptal basal segments. Moreover, the LV dilatation was 
reduced, with smaller volume and an increased myocardial mass. No arrhythmia was 
detected by 24 hrs Holter monitoring.   
We believe CD133+ stem cells to be amongst the most potent cells for myocardial repair. 
This work represents the first Canadian experience with CD133+ stem cells for the treatment 
of chronic ischemic cardiomyopathy. The remarkable and encouraging results from the fist 
patient support the continuation of IMPACT-CABG trial, and by randomization between 
CABG combined to stem cell versus CABG alone, this trial will prove the safety of the 
procedure and possibly the beneficial effects of the cellular therapy. This novel therapy may 
become an important therapeutical adjunct to conventional treatment for coronary artery 
diseases. 
6. Pitfalls and important issues on cell therapy 
Although great enthusiasm was created by the possibility of reconstituting the damaged 
heart by cell therapy, the exact mechanism is still unclear, and it is possible that findings 
supporting myocardial regeneration by stem cells differentiation possibly result form 
technical artifacts. Controversy exists surrounding the ability of BMSC to undergo 
transdifferentiation, as some techniques that have been used to demonstrate this 
phenomenon have been questioned (Grigoropoulos and Mathur, 2006).  Current failure to 
label the donor cells adequately and to follow them in vivo makes it very difficult to 
distinguish them from background tissue and could lead to misinterpretation (Hassink, et 
al., 2003).  Indeed, the use of GFP reporter gene is attractive because it is compatible with a 
variety of imaging techniques, but dead and dying cardiomyocytes have an autofluorescent 
spectrum that partially overlaps with that of GFP. (Burdon, et al., 2011) After injury, 
autofluorescence increases due to accumulated lipofuscin, blood-derived pigments, and 
other intrinsic fluors such as flavins and reduced nicotinamide adenine dinucleotide 
(NADH) (Laflamme and Murry, 2005).  Evidence for regeneration includes colocalization of 
GFP fluorescence from donor cells, with immunostaining for cardiomyocytes markers, 
including sarcomeric actin.  Thus, it is possible to misidentify a GFP positive cardiomyocyte 
as the result from a donor GFP positive cell.  
An important issue limiting cell therapy is the extensive cell death following transplantation 
into the ischemic heart.  The survival of implanted cells is often limited in the infarcted 
tissue (Koc and Gerson, 2003, Zhang, et al., 2001) and cell death is worsened by the hostile 
environment caused by the reduced blood flow, hypoxemia, inflammation and scarring in 
the ischemic myocardium.  Regardless of cell type, multiple studies suggest that more than 
90% of cells successfully delivered to the heart will die within one week (Laflamme and 
Murry, 2005, Noiseux, et al., 2006, Zhang, et al., 2001).  Most cells die within hours of 
transplantation because of interplay of ischemia, inflammation, and apoptosis. (Menasche, 
2009, Rosenzweig, 2006) Recent clinical trials yielded inconsistent data in cardiac function 
reporting mixed results. (Janssens, et al., 2006, Lunde, et al., 2006, Schachinger, et al., 2006) 
These conflicting data have re-ignited interest in the unresolved questions regarding the 
biology of candidate cells, and how to improve these cells for clinical therapy. Our group 
investigated the over-expression of anti-apoptotic proteins such as Akt, to improve the cell 
survival, but also the reparative effects of MSC therapy in an animal model of acute MI 
(Gnecchi, et al., 2005, Gnecchi, et al., 2006, Mangi, et al., 2003, Noiseux, et al., 2006).  We 
genetically engineered MSC to over-express the pro-survival gene Akt1 (Datta, et al., 1999, 
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Franke, et al., 2003, Franke, et al., 1997) (Akt-MSC).  Akt over-expression resulted in better 
protective and anti-apoptotic effects against ischemia in vitro, but also in vivo as shown by 
the reduction of the proportion of apoptotic cells following implantation into rat infarcted 
myocardium and increased cell retention.  Moreover, intra-cardiac injection of 5x106 Akt-
MSC inhibited the process of cardiac remodeling and resulted in normalization of cardiac 
function at 2 weeks, to a level indistinguishable from sham-operated animals (Mangi, et al., 
2003). Although improvements in cardiac function were also observed in other studies, 
complete recovery of LV function occurred only following transplantation of MSC over-
expressing Akt, and these results represent a new threshold in cardiac regeneration using 
cell therapy (Koc and Gerson, 2003). This cell-based therapy, combined with a gene-therapy 
approach, has the potential to address multiple issues in cell availability and scalability. 
A clear understanding of events stimulated by and consequent of transplant of various cell 
types is critical to avoid potentially adverse consequences. (Evans, et al., 2007) In particular, 
appropriate electrical and mechanical coupling in the myocardium is essential for optimal 
cardiac function and avoiding lethal arrhythmias such as observed with skeletal myoblasts. 
An additional issue of possible concern may be tumorigenesis. (Evans, et al., 2007) Recent 
experimental study demonstrated that engraftment of undifferentiated embryonic stem cells 
into the myocardium could result in tumor formation. (Cai, et al., 2007) 
The identification of the appropriate route for cell administration to the damaged heart is an 
essential prerequisite for successful tissue repair (Strauer and Kornowski, 2003). The goal of 
any cell delivery strategy is to transplant sufficient number of cells into the myocardial 
region of interest and to achieve maximum retention of cells within that area (Kocher, et al., 
2007). Furthermore, the success of cell delivery is determined by the local milieu since it will 
influence short-term cell survival, cell properties in regard to cell adhesion, transmigration 
through the vascular wall, and tissue invasion.   High cell concentrations within the area of 
interest and prevention of homing of transplanted cells into other organs are required, 
therefore targeted and regional administration of cells are preferred (Strauer and 
Kornowski, 2003). Cell homing, adhesion, transmigration through the vascular wall, and 
tissue invasion involves many complex steps. 
The most frequently used routes of cell delivery for ischemic cardiomyopathy are 
percutaneous intra-coronary injection, percutaneous endomyocardial using 3D-guiding 
systems, and direct intra-myocardial injection during open chest cardiac surgery procedure. 
Intra-coronary sinus or intravenous systemic deliveries have also been described, as well as 
stem cell mobilization following G-CSF treatment as described in the FIRSTLINE-AMI trial 
(Ince, et al., 2005)5. Intra-coronary infusion requires migration through the vessel wall into 
the ischemic heart tissue, which is helped by damaged and permeabilized endothelium as 
found after acute myocardial infarct. Cells like bone marrow-derived and blood-derived 
progenitor cells are known to extravasate and migrate efficiently into ischemic areas, 
whereas skeletal myoblasts do not (Kocher, et al., 2007). The intravenous route is the easiest, 
but the main disadvantage is that approximately only 3% of normal cardiac output will flow 
through the left ventricle via the coronary arteries, and is limited because of transpulmonary 
first-pass captation and sequestration (Strauer and Kornowski, 2003).  
The intra-coronary route has been used safely and effectively to achieve selective 
administration and higher first-pass delivery to the heart than systemic therapy (Psaltis, et 
al., 2008). However, there have been reports of micro-circulation obstruction following intra-
coronary infusion of satellite cells and MSC, resulting in embolic myocardial damage and 
sub-acute microinfarction (Vulliet, et al., 2004). Unlike intra-vascular infusion, direct intra-
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myocardial injection targets specific regions of myocardium without relying on the up-
regulation of inflammatory signals to assist transvascular cell migration and tissue invasion 
(Psaltis, et al., 2008).  Pre-clinical and clinical results suggest that direct MSC injection may 
result in less non-cardiac cell entrapment than intra-coronary or systemic intravenous 
infusion, along with better retention culminating in greater benefit for cardiac function 
recovery (Freyman, et al., 2006, Heldman and Hare, 2008, Perin, et al., 2008). An intra-
myocardial injection delivery approach appears specially well-suited for transplantation of 
larger and adherent cells (e.g. MSC) and particularly relevant to chronic myocardial diseases 
such as chronic ischemic cardiomyopathy or dilated failing heart (Psaltis, et al., 2008). After 
more than a decade since the beginning of cell therapy, no one has identified the technique 
for optimal administration of stem cell into the heart.  As a result, more than 90% of the cells 
delivered to the heart through a needle are lost to the circulation or leak out of the injection 
site (Laflamme and Murry, 2005).  Indeed, mechanical leakage and washout may account for 
a major proportion of cell loss after cell implantation (Kocher, et al., 2007). Experiments by 
Teng et al with microspheres revealed a retention rate of only 11% following direct intra-
myocardial injection in the beating porcine heart versus 67% in the non-beating heart 
illustrate the complexity of the approach (Teng, et al., 2006).  
7. Conclusion 
The initial hypothesis underpinning cell therapy was that new muscle cells would be 
generated in the injured myocardium, and this would restore cardiac function through 
systolic force generation (Laflamme, et al., 2007). Although the prospect of cardiac tissue 
regeneration provided an initial stimulus for cell-based therapies, subsequent experimental 
work has questioned the ability of stem cells to effectively regenerate cardiomyocytes 
(Murry, et al., 2004, Noiseux, et al., 2006). Unfortunately, hardly any clinical studies 
demonstrated convincing evidence for electrical or mechanical activation of engrafted cells 
within the infarct. There is currently uncertainty as to the optimal stem cell population to 
use clinically for cardiac repair. It appears that not “one cell fits all” but that the selection of 
the cell type should be tailored to the primary clinical indication and expected outcome 
(Menasche, 2009). Despite recent significant progress, answer to basic questions such as the 
best cell type has not been addressed so far. Different cell type may compete for the 
engraftment in the injured myocardium. The fact that numerous cell types and preparations 
can enhance myocardial repair, when none of these cells can even generate new 
cardiomyocytes, suggests that multiple mechanisms may be implicated.  Presently, the field 
of stem cell therapy in regenerative medicine has extremely limited insight about how any 
candidate cell or treatment may work (Laflamme, et al., 2007). Indeed, the mechanisms 
responsible for the improvement in cardiac function have not yet been elucidated, and 
clinical studies have suggested that only a small fraction of implanted cells survived in the 
heart (Rosenzweig, 2006).  This lack of mechanistic understanding has not prevented rapid 
clinical translation of cellular therapy, and numerous trials have been recently initiated.  
Recent randomized studies of cell therapy represent a milestone in this rapidly developing 
field, while serving as a cogent reminder that many important clinical and fundamental 
questions have yet to be addressed in carefully designed human studies (Rosenzweig, 2006). 
While stem cell therapy trials in cardiovascular disease are promptly progressing from 
bench to bedside, more extensive and vigorous basic science and clinical research are clearly 
needed to thoroughly investigate the therapeutic merits and potential adverse effects of 
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stem cell transplantation (Jain, et al., 2005). Over the past few years, several promising 
results have been reported, but many hurdles remain before cell therapy can actually be 
commonly applied to treat patients with damaged hearts (Smits, et al., 2005). With a better 
understanding of adult stem cell biology and of the underpinning mechanisms involved in 
myocardial repair, we may eventually harness the therapeutic potential of these unique cells 
to better fulfill the beneficial promise of regenerative medicine in future years to come. 
Nevertheless, it appears that the exact mechanism underlying stem cell therapy is far more 
complex that previously anticipated, but so far cardiac cell therapy is feasible and overall 
safe in the clinical arena. 
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